Rosiglitazone and cardiovascular risk

MeSH terms

• Adverse Drug Reaction Reporting Systems
• Cardiovascular Diseases / mortality*
• Clinical Trials, Phase IV as Topic
• Diabetes Mellitus, Type 2 / drug therapy*
• Drug Approval / legislation & jurisprudence*
• Humans
• Hypoglycemic Agents / adverse effects*
• Meta-Analysis as Topic
• Myocardial Infarction / chemically induced*
• Randomized Controlled Trials as Topic
• Risk Assessment
• Rosiglitazone
• Thiazolidinediones / adverse effects*
• United States
• United States Food and Drug Administration